Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
WuXi XDC Cayman, Inc. ( (HK:2268) ) just unveiled an update.
WuXi XDC Cayman Inc. announced the successful passing of all proposed resolutions at its extraordinary general meeting held on December 12, 2025. These resolutions included the approval of revised service fees and new master services agreements with WuXi Biologics and WuXi AppTec, which are set to enhance the company’s operational framework and strategic partnerships. The unanimous approval by shareholders indicates strong support for the company’s future plans and collaborations, potentially strengthening its position in the biotechnology sector.
The most recent analyst rating on (HK:2268) stock is a Buy with a HK$90.00 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.
More about WuXi XDC Cayman, Inc.
WuXi XDC Cayman Inc. operates in the biotechnology industry, focusing on biologics and related services. The company is involved in providing master services agreements for antibodies and payload-linkers, collaborating with entities like WuXi Biologics and WuXi AppTec.
Average Trading Volume: 5,573,512
Technical Sentiment Signal: Buy
Current Market Cap: HK$88.48B
For detailed information about 2268 stock, go to TipRanks’ Stock Analysis page.